Kuanoniamine A

Kuanoniamine A is a pyridoacridine alkaloid and also an anticancer agent. Kuanoniamine A inhibits DNA synthesis, induces apoptosis, and regulates the cell cycle by reducing the proportion of cells in the G2/M phase. Kuanoniamine A inhibits the proliferation of human lymphocytes. Kuanoniamine A can be used in research related to breast cancer, glioma, non-small cell lung cancer, and melanoma^[1]. In Vitro:Kuanoniamine A (48 h) potently inhibits the growth of MCF-7, MDA-MB-231, NCI-H460, SF-268, UACC-62, and MRC-5 cells with GI₅₀ values ranging from 0.12 to 4.67 μM after 48 h of continuous exposure^[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) potently inhibits DNA synthesis in MCF-7 cells, with a concentration-dependent effect that reduces thymidine incorporation by over 60% at 0.08 μM across 6, 12, 24, and 48 h exposure times^[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) reduces MCF-7 cell viability in a time-dependent manner, decreasing viability to 70% at 0.04 μM after 6 h exposure, with more severe reductions after 24 and 48 h^[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) reduces cellular protein content in MCF-7 cells in a time-dependent manner, with effects mirroring its impact on cell viability measured by the MTT assay^[1].
Kuanoniamine A (0.34 μM; 24 h) reduces the proportion of MCF-7 cells in G2/M phase, accumulates cells in G1 phase, and decreases the S phase fraction relative to untreated control cells^[1].
Kuanoniamine A (0.5-1.0 μM; 24 h) increases the number of apoptotic MCF-7 cells relative to untreated control cells^[1].
Kuanoniamine A (0.5-2.5 μM; 24 h) reduces MCF-7 cell viability to ≥70% at 0.5 and 1.0 μM after 24 h, while 2.5 μM drastically reduces viability to 35.7%^[1].
Kuanoniamine A (0.12-86.51 μM; 96 h) potently inhibits PHA-induced proliferation of human lymphocytes with an IC₅₀ of 1.50 μM after 96 h of continuous exposure^[1].